Literature DB >> 36043968

A non-invasive combined strategy to improve the appropriateness of upper gastrointestinal endoscopy.

Kryssia Rodriguez1, Marilisa Franceschi2, Antonio Ferronato3, Lorenzo Brozzi4, Antonio Antico5, Maria Piera Panozzo6, Arianna Massella7, Barbara Pertoldi8, Alice Morini9, Alberto Barchi10, Michele Russo11, Pellegrino Crafa12, Lorella Franzoni13, Lucio Cuoco14, Gianluca Baldassarre15, Francesco Di Mario16.   

Abstract

Background and aim Increasing the appropriateness of upper gastrointestinal endoscopy (UGIE) improves the quality of care while containing costs. The aim of this study was to improve the appropriateness of UGIE through a process involving evaluation of prescriptions and the use of a non-invasive alternative. Materials and methods A senior endoscopist evaluated the appropriateness of all outpatient referrals for UGIE and established the proper timing. Referrals were either accepted and programmed, canceled, or substituted by a non-invasive evaluation of gastric function, determining serum levels of gastrin-17 (G17), Pepsinogen I (PGI) and II (PGII), and antibodies against Helicobacter pylori. Results A total of 5102 requests for UGIE examinations were evaluated; 540 (10.4%) were inappropriate and had been prescribed for: gastroesophageal reflux disease (n=307), surveillance with erroneous timing (n=113), dyspepsia (n=66), other indications (n=20), and absence of written indication (n=34). Gastric function was evaluated in 282/540 patients; findings included normal values in 94 patients without proton-pump inhibitor therapy (PPI) and in 48 on PPI, active H pylori infection in 56, previous H pylori infection in 30, GERD in n=50, and atrophic gastritis in n=4. UGIE was performed in the latter 4 cases.  Within 2 years (range 1-22 months) of the initial refusal, 105/504 patients underwent UGIE, with normal endoscopic findings in 71/105 (67.5%), and with no cases of cancer. Conclusions This strategy, based on a strict control of prescriptions, is effective to increase the appropriateness while containing public health costs. The use of gastric function testing improves patient selection for UGIE endoscopy.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36043968      PMCID: PMC9534244          DOI: 10.23750/abm.v93i4.12772

Source DB:  PubMed          Journal:  Acta Biomed        ISSN: 0392-4203


  38 in total

1.  Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD.

Authors:  Francesco Di Mario; Pellegrino Crafa; Marilisa Franceschi; Kryssia Rodriguez-Castro; Gianluca Baldassarre; Antonio Ferronato; Antonio Antico; Maria Piera Panozzo; Lorella Franzoni; Alberto Barchi; Michele Russo; Nicola De Bortoli; Matteo Ghisa; Edoardo Savarino
Journal:  J Gastrointestin Liver Dis       Date:  2021-02-12       Impact factor: 2.008

2.  Gastric cancer screening using the serum pepsinogen test method.

Authors:  Kazumasa Miki
Journal:  Gastric Cancer       Date:  2006-11-24       Impact factor: 7.370

3.  The new modified ABCD method for gastric neoplasm screening.

Authors:  Chan Hyuk Park; Eun Hye Kim; Da Hyun Jung; Hyunsoo Chung; Jun Chul Park; Sung Kwan Shin; Sang Kil Lee; Yong Chan Lee
Journal:  Gastric Cancer       Date:  2015-02-08       Impact factor: 7.370

4.  Performance of gastric cancer screening by endoscopy testing through the National Cancer Screening Program of Korea.

Authors:  Kui Son Choi; Jae Kwan Jun; Hoo-Yeon Lee; Sohee Park; Kyu Won Jung; Mi Ah Han; Il Ju Choi; Eun-Cheol Park
Journal:  Cancer Sci       Date:  2011-06-09       Impact factor: 6.716

5.  A nine-year audit of open-access upper gastrointestinal endoscopic procedures: results and experience of a single centre.

Authors:  Dean Keren; Tova Rainis; Edy Stermer; Alexandra Lavy
Journal:  Can J Gastroenterol       Date:  2011-02       Impact factor: 3.522

6.  Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach.

Authors:  Katsunori Iijima; Yasuhiko Abe; Ryosuke Kikuchi; Tomoyuki Koike; Shuichi Ohara; Pentti Sipponen; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

7.  Burden of gastrointestinal disease in the United States: 2012 update.

Authors:  Anne F Peery; Evan S Dellon; Jennifer Lund; Seth D Crockett; Christopher E McGowan; William J Bulsiewicz; Lisa M Gangarosa; Michelle T Thiny; Karyn Stizenberg; Douglas R Morgan; Yehuda Ringel; Hannah P Kim; Marco Dacosta DiBonaventura; Charlotte F Carroll; Jeffery K Allen; Suzanne F Cook; Robert S Sandler; Michael D Kappelman; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2012-08-08       Impact factor: 22.682

8.  ASGE guidelines for the appropriate use of upper endoscopy: association with endoscopic findings.

Authors:  Angelo Rossi; Gianluca Bersani; Giorgio Ricci; Giovanni Defabritiis; Valeria Pollino; Alessandra Suzzi; Beatrice Gorini; Vittorio Alvisi
Journal:  Gastrointest Endosc       Date:  2002-11       Impact factor: 9.427

Review 9.  Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method".

Authors:  Kazumasa Miki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2011       Impact factor: 3.493

10.  Accuracy of endoscopic staging and targeted biopsies for routine gastric intestinal metaplasia and gastric atrophy evaluation study protocol of a prospective, cohort study: the estimate study.

Authors:  Stella A V Nieuwenburg; William W Waddingham; David Graham; Manuel Rodriguez-Justo; Katharina Biermann; Ernst J Kuipers; Matthew Banks; Marnix Jansen; Manon C W Spaander
Journal:  BMJ Open       Date:  2019-09-18       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.